The Beneficial Effects of Switching from Oral Iron to IV FCM in Ckd Patients


Dr (Prof) DK Agarwal, New Delhi    11 January 2018

  1. The most common approach of treatment of patients with nondialysis-dependent (ND-CKD) is the use of erythropoiesis-stimulating agents (ESA) and oral iron treatment.
  2. A prospective, single arm and single center study including adult patients with ND-CKD was conducted to evaluate the effect of a switch from oral iron to intravenous ferric carboxymaltose (IV FCM).
  3. The study results showed that among patients with ND-CKD and stable or normal/borderline hemoglobin(HB), switching from oral iron to IV FCM was associated with significant improvement in hematological and iron parameters and a significant reduction in ESA dose requirements.
  4. The study results did not report any adverse events related to the use of FCM.
  5. The results of the trial suggested that a single IV FCM dose of 1,000 mg iron was effective in reducing monthly ESA dose requirements along with associated treatment costs; maintaining recommended target Hb levels and increasing the iron parameters to target levels in patient with ND-CKD who had 6 months oral iron treatment before switching to FCM.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.